Brisbane, Australia, 2 October 2018 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has completed recruitment in its prospective, double-blind, in-laboratory sleep apnoea clinical study with 600 patients recruited. The company is working with Dr Philip Currie and Dr Ivan Ling of Cardio Respiratory Sleep (CRS) to recruit patients at Hollywood Private Hospital and The Park Private Hospital in Perth, Australia.
ResApp previously announced that it had developed a sound-based algorithm that identified moderate and severe OSA using a smartphone placed on a bedside table with a proof-of-concept study of 731 patients showing 86% sensitivity and 83% specificity when compared to simultaneous in-laboratory polysomnography. ResApp is looking to confirm these findings in its prospective, double-blind study.
Dr Philip Currie, the study Principal Investigator and CEO of CRS commented, “Recruitment of 600 patients represents one of the largest prospective clinical studies ever undertaken for sleep apnoea diagnosis and we want to thank the patients who participated in the study as well as the team at CRS for their considerable skill in completing the study. There is a large clinical need for reducing the number of people with undiagnosed sleep apnoea and a scalable, accurate and easy to use smartphone-based screening test could significantly improve the health of a large portion of the adult population.”
With recruitment complete, data verification will now be performed and top-line results should be available within a week.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies are underway at leading hospitals in the United States and Australia, and previous studies have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a proof-of-concept clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.